Werewolf Therapeutics (HOWL) Expected to Release Earnings on Tuesday

Werewolf Therapeutics (NASDAQ:HOWL) is anticipated to post its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $18.31 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 8:30 AM ET.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.36. The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $21.00 million. On average, analysts expect Werewolf Therapeutics to post ($0.89) EPS for the current fiscal year and ($0.59) EPS for the next fiscal year.

Werewolf Therapeutics Stock Performance

Shares of NASDAQ:HOWL opened at $0.98 on Tuesday. The firm has a market cap of $47.66 million, a price-to-earnings ratio of -1.29 and a beta of 0.51. The firm has a fifty day moving average price of $0.92 and a 200 day moving average price of $0.67. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $1.83.

Analysts Set New Price Targets

Several research firms have commented on HOWL. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Wall Street Zen raised Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 5th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Werewolf Therapeutics currently has an average rating of “Hold” and an average target price of $4.00.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer treatments that stimulate the immune system. The company’s approach is designed to activate immune responses within the tumor microenvironment while limiting exposure to healthy tissues.

Werewolf’s technology platform, known as INDUKINE, uses conditionally activated cytokines. These therapeutic proteins are intended to remain inactive in the bloodstream and become activated primarily in tumors, where they may help recruit and enhance immune cells to attack cancer.